Colistin is a last-resort antibiotic that is usually only used for severe infections with resistant bacteria. This is due to its severe kidney-damaging side effects, which occur in about 30% of treated patients. A research team at the Helmholtz Center for Infection Research (HZI) and the German Center for Infection Research (DZIF) has now been able to produce an inactivated, harmless form of colistin that is only activated in the body with the help of chemical switches.
Source:
phys.org